Celgene Corp (CELG.O)

CELG.O on Nasdaq

116.09USD
22 May 2015
Change (% chg)

$-0.11 (-0.09%)
Prev Close
$116.20
Open
$115.50
Day's High
$116.54
Day's Low
$114.92
Volume
2,651,131
Avg. Vol
5,300,741
52-wk High
$129.06
52-wk Low
$74.00

CELG.O

Chart for CELG.O

About

Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company’s commercial stage products include REVLIMID, VIDAZA, ABRAXANE, POMALYST/IMNOVID, THALOMID, ISTODAX and... (more)

Overall

Beta: 1.00
Market Cap(Mil.): $92,076.13
Shares Outstanding(Mil.): 793.14
Dividend: --
Yield (%): --

Financials

  CELG.O Industry Sector
P/E (TTM): 39.66 37.22 39.17
EPS (TTM): 2.93 -- --
ROI: 19.01 16.24 15.58
ROE: 43.36 16.99 16.57
Search Stocks

EU patent office revokes Celgene Revlimid patent; appeal planned

- Celgene Corp on Thursday said the European Patent Office revoked a key patent on the company's flagship multiple myeloma drug Revlimid, a move that could shave a year or two from the medicine's exclusivity in Europe.

07 May 2015

UPDATE 1-EU patent office revokes Celgene Revlimid patent; appeal planned

May 7 - Celgene Corp on Thursday said the European Patent Office revoked a key patent on the company's flagship multiple myeloma drug Revlimid, a move that could shave a year or two from the medicine's exclusivity in Europe.

07 May 2015

EU patent office revokes Celgene Revlimid patent; appeal planned

May 7 - Celgene Corp on Thursday said the European Patent Office revoked a key patent on the company's flagship multiple myeloma drug Revlimid, a move that could shave a year or two from the medicine's exclusivity in Europe.

07 May 2015

Rich Synageva M&A premium epitomizes appetite for orphan drugs

- The hefty premium Alexion Pharmaceuticals Inc has agreed to pay to acquire Synageva BioPharma Corp highlights how the popularity of so-called orphan drug makers is leading to valuations many investors now deem frothy.

06 May 2015

CORRECTED-Rich Synageva M&A premium epitomizes appetite for orphan drugs

May 6 - The hefty premium Alexion Pharmaceuticals Inc has agreed to pay to acquire Synageva BioPharma Corp highlights how the popularity of so-called orphan drug makers is leading to valuations many investors now deem frothy.

06 May 2015

US STOCKS-Wall St drops with tech shares; LinkedIn falls late

* Indexes down: Dow 1.1 pct, S&P 1 pct, Nasdaq 1.6 pct (Updates close with LinkedIn, solar company shares down after the bell, Gilead up, small caps down, new quote)

30 Apr 2015

US STOCKS-Wall St drops with tech shares; indexes up for month

* Indexes down: Dow 1.1 pct, S&P 1 pct, Nasdaq 1.6 pct (Updates to close)

30 Apr 2015

Celgene sales highlight Revlimid dependence ahead of patent ruling

- Celgene Corp's dependence on its big-selling multiple myeloma drug Revlimid raised investor concerns on Thursday as sales of its other medicines fell short of expectations.

30 Apr 2015

Celgene sales highlight Revlimid dependence ahead of patent ruling

April 30 - Celgene Corp's dependence on its big-selling multiple myeloma drug Revlimid raised investor concerns on Thursday as sales of its other medicines fell short of expectations.

30 Apr 2015

US STOCKS-Wall St drops with tech shares; Nasdaq down for 4th day

* Indexes down: Dow 1.4 pct, S&P 1.3 pct, Nasdaq 1.9 pct (Updates to late afternoon)

30 Apr 2015

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥6,008 +33.00
Eisai Co., Ltd (4523.T) ¥8,186 +221.00
Johnson & Johnson (JNJ.N) $101.35 -1.07
Pfizer Inc. (PFE.N) $34.28 -0.08
Novartis AG (NOVN.VX) CHF98.10 +0.05
Merck & Co., Inc. (MRK.N) $59.38 -0.72
Roche Holding Ltd. (ROG.VX) CHF277.90 -1.30
Abbott Laboratories (ABT.N) $49.03 -0.31
Sanofi SA (SASY.PA) €92.30 -0.08
AstraZeneca plc (AZN.L) 4,473.50p +48.50

Earnings vs. Estimates

Search Stocks